Method of restoring ciliated cell motility
OwnerRam K. Menon, Mark A. Sperling +3inventors
InventorsRam K. Menon, Mark A. Sperling, Chunxia Lu, Selma Witchel, John Kasik
Life of this patent
Estimating the term…
Loading patent…
OwnerRam K. Menon, Mark A. Sperling +3inventors
InventorsRam K. Menon, Mark A. Sperling, Chunxia Lu, Selma Witchel, John Kasik
Estimating the term…
The present invention relates to a novel gene from the insulin family, Insl6, which expresses a protein restoring motility in ciliated cells. The proteins of the insulin family play essential roles in pleiotropic physiological processes affecting metabolism, growth, and reproduction. A new member of the insulin family named Insl6 is disclosed playing an essential role in ciliated cell activity. Insl6 plays an essential role in spermatocyte function. Thus, the Insl6 gene and its protein product are useful in the treatment of infertility caused by the loss of spermatocyte motility. A method of modulating male fertility is disclosed.
A method for modulating male fertility in a male subject comprising regulating the in vivo expression of an INSL6 gene of SEQ ID No. 3.
A method for enhancing fertility of a male subject comprising the steps of administering an effective amount of Insl6 protein of SEQ ID No. 4 to the subject's sperm during in vitro fertilization to improve capacitance of the sperm.
A method for restoring sperm motility of a male subject comprising administering an effective amount of Insl6 protein of SEQ ID No. 4 to the subject's sperm during in vitro fertilization.
A method for promoting development in a male embryo comprising delivering to said male embryo an effective amount of a vector comprising a nucleic acid encoding an Insl6 protein or a protein having substantial homology to the protein of SEQ ID No. 4 to induce expression of the INSL6 protein of SEQ ID No. 4.
A method for regulating levels of INSL6 protein of SEQ ID No. 4 comprising the step of regulating the degradation of INSL6 protein.
A method for regulating levels of INSL6 protein of SEQ ID No. 4 comprising the step of enhancing synthesis of INSL6 protein.
A composition for modulating male fertility comprising an effective amount of a protein of SEQ ID. No. 2 encoded by an INSL6 nucleic acid of SEQ ID No. 3, and a pharmaceutical carrier wherein said protein is incorporated into said pharmaceutical carrier.
A composition for modulating male fertility comprising an effective amount of a substance selected from the group consisting of a repressor of the INSL6 gene, a promoter of the INSL6 gene, a nucleic acid complementary to the cDNA of INSL6 gene, and a nascent-transcript-terminating nucleic acid complementary to the INSL6 gene, and a pharmaceutically suitable carrier.
An isolated and purified expression vector comprising a control nucleic acid sequence operatively linked to an isolated and purified nucleic acid insert encoding a protein substantially identical to the INSL6 protein of SEQ ID No. 4.
A stably transformed cell line stably expressing a substantially identical protein to a INSL6 protein of SEQ ID No. 4.
A method for modulating male fertility comprising mutating the INSL6 gene of SEQ ID No. 3 at nucleotide number 22 whereby codon number 8 is changed from a serine-encoding codon to a threonine-encoding codon.
The method for modulating male infertility comprising mutating the INSL6 gene of SEQ ID No. 3 at nucleotide number 22 whereby codon number 8 is changed from a theonine-encoding codon to a serine-encoding codon.
An isolated and purified antibody or fragment thereof which specifically binds to a polypeptide of SEQ ID No. 4.
An isolated and purified antibody or fragment thereof which specifically binds to a polypeptide of SEQ ID No.2.
A method of modulating male fertility comprising modulating cyclic-AMP levels to modulate INSL6 activity in sperm cells.
A method for modulating male fertility comprising modulating a proteasome pathway to modulate INSL6 activity.
A method of diagnosing a mutation or deletion in a the INSL6 sequence of a subject comprising determining allelic homozygocity or heterozygocity of said subjects INSL6 by hybridizing in a Southern blot with marker probe selected from the group consisting of D9S251, D9S248, D9S256, DS1686, D9S1873, D9S1792, and D9S1858.
A method for modulating male fertility in a male subject comprising regulating the in vivo expression of an insulin 6 gene.
Dependencies are inferred from the claim text.